Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Calmodulin antagonists' binding sites on calmodulin.

T Tanaka, T Ohmura, H Hidaka

    Pharmacology
    |January 1, 1983
    PubMed
    Summary

    Troponin I inhibits calmodulin (CaM) binding of W-7 and TFP. Methionine oxidation in CaM blocks antagonist binding and reduces CaM activity, suggesting key binding sites.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Anti-immunoglobulin M activates nuclear calcium/calmodulin-dependent protein kinase II in human B lymphocytes.

    The Journal of experimental medicine·1995
    Same author

    Elucidation of the protein kinase C-dependent apoptosis pathway in distinct subsets of T lymphocytes in MRL-lpr/lpr mice.

    European journal of immunology·1995
    Same author

    Purification and characterization of a novel protein activator of Ca2+/calmodulin-dependent protein kinase I.

    Biochemical and biophysical research communications·1995
    Same author

    Effect of KN-62, Ca2+/calmodulin-dependent protein kinase II inhibitor, on adriamycin resistance of human ovarian cancer cells.

    Biochemical and biophysical research communications·1995
    Same author

    The regulatory region of calcium/calmodulin-dependent protein kinase I contains closely associated autoinhibitory and calmodulin-binding domains.

    The Journal of biological chemistry·1995
    Same author

    Prophylaxis of genetically determined diabetes by diazoxide: a study in a rat model of naturally occurring obese diabetes.

    The Journal of pharmacology and experimental therapeutics·1995

    Area of Science:

    • Biochemistry
    • Neuroscience

    Background:

    • Calmodulin (CaM) is a crucial calcium-binding protein involved in numerous cellular processes.
    • CaM antagonists like W-7 and trifluoperazine (TFP) are used to study CaM function.

    Purpose of the Study:

    • To investigate the binding sites of CaM antagonists on calmodulin.
    • To elucidate the role of specific CaM residues in antagonist binding and activity.

    Main Methods:

    • Studied the effect of Troponin I on the binding of [3H]-W-7 and [3H]-TFP to bovine brain calmodulin.
    • Performed selective chemical modifications of CaM residues (methionine, histidine, tyrosine, arginine).
    • Assessed the impact of modifications on antagonist binding and CaM's ability to stimulate phosphodiesterase.

    Main Results:

    • Troponin I inhibited W-7 and TFP binding to CaM in a concentration-dependent manner.
    • Oxidation of methionine residues in CaM significantly reduced W-7, TFP, and chlorpromazine binding, alongside loss of CaM activity.
    • Modification of histidine, tyrosine, and arginine residues did not affect W-7 binding or CaM activity.

    Conclusions:

    • The binding sites for W-7 and TFP on calmodulin are likely located between the second and third Ca2+-binding loops.
    • Methionine residues in calmodulin appear critical for the binding of these antagonists and for CaM's biological activity.

    Related Experiment Videos